Impact of a TLR9 Agonist and Broadly Neutralizing Antibodies on HIV-1 Persistence: The Randomized Phase IIa Titan Trial

In this Phase IIa, placebo-controlled, double-blinded trial, 43 people with HIV-1 on antiretroviral therapy were randomized to placebo/placebo, lefitolimod/placebo, placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs) or lefitolimod/bNAb.